Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Lenalidomide and thalidomide in the treatment of chronic pain.

Asher C, Furnish T.

Expert Opin Drug Saf. 2013 May;12(3):367-74. doi: 10.1517/14740338.2013.775242. Epub 2013 Feb 27. Review.

PMID:
23442012
2.

Use of lenalidomide in treating refractory prurigo nodularis.

Liu H, Gaspari AA, Schleichert R.

J Drugs Dermatol. 2013 Mar;12(3):360-1.

PMID:
23545923
3.

Novel immunomodulatory compounds in multiple myeloma.

Saini N, Mahindra A.

Expert Opin Investig Drugs. 2013 Feb;22(2):207-15. doi: 10.1517/13543784.2013.749235. Epub 2012 Dec 25. Review.

PMID:
23265189
4.

Lenalidomide in the treatment of chronic lymphocytic leukemia.

Gentile M, Recchia AG, Vigna E, Mazzone C, Lucia E, Gigliotti V, Bossio S, Madeo A, Morabito L, Servillo P, Franzese S, Caruso N, De Stefano L, Bisconte MG, Gentile C, Morabito F.

Expert Opin Investig Drugs. 2011 Feb;20(2):273-86. doi: 10.1517/13543784.2011.546343. Epub 2011 Jan 10. Review.

PMID:
21214505
5.

Lenalidomide for complex regional pain syndrome type 1: lack of efficacy in a phase II randomized study.

Manning DC, Alexander G, Arezzo JC, Cooper A, Harden RN, Oaklander AL, Raja SN, Rauck R, Schwartzman R.

J Pain. 2014 Dec;15(12):1366-76. doi: 10.1016/j.jpain.2014.09.013. Epub 2014 Oct 2.

6.

Thalidomide-derived immunomodulatory drugs as therapeutic agents.

Galustian C, Labarthe MC, Bartlett JB, Dalgleish AG.

Expert Opin Biol Ther. 2004 Dec;4(12):1963-70. Review.

PMID:
15571458
7.

Thalidomide and lenalidomide in multiple myeloma.

Mazumder A, Jagannath S.

Best Pract Res Clin Haematol. 2006;19(4):769-80. Review.

PMID:
16997182
8.

Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.

Bringhen S, Gay F, Pautasso C, Cerrato C, Boccadoro M, Palumbo A.

Expert Opin Drug Metab Toxicol. 2012 Sep;8(9):1209-22. doi: 10.1517/17425255.2012.712685. Epub 2012 Aug 3. Review.

PMID:
22862790
9.

Lenalidomide: an immunomodulatory drug.

Crane E, List A.

Future Oncol. 2005 Oct;1(5):575-83. Review.

PMID:
16556034
10.

The potential of immunomodulatory drugs in the treatment of solid tumors.

Dalgleish A, Galustian C.

Future Oncol. 2010 Sep;6(9):1479-84. doi: 10.2217/fon.10.105. Review.

PMID:
20919830
11.

[IMiDs in hematology].

Wémeau M, Gauthier J, Leleu X, Yakoub-Agha I.

Bull Cancer. 2011 Aug;98(8):879-87. doi: 10.1684/bdc.2011.1404. Review. French.

12.

The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.

Leitch HA, Buckstein R, Shamy A, Storring JM.

Crit Rev Oncol Hematol. 2013 Feb;85(2):162-92. doi: 10.1016/j.critrevonc.2012.07.003. Epub 2012 Aug 15. Review.

PMID:
22901762
13.

IMiDs: a novel class of immunomodulators.

Knight R.

Semin Oncol. 2005 Aug;32(4 Suppl 5):S24-30. Review.

PMID:
16085014
14.

A review of the history, properties, and use of the immunomodulatory compound lenalidomide.

Zeldis JB, Knight R, Hussein M, Chopra R, Muller G.

Ann N Y Acad Sci. 2011 Mar;1222:76-82. doi: 10.1111/j.1749-6632.2011.05974.x. Review.

PMID:
21434945
15.

Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.

Maier SK, Hammond JM.

Ann Pharmacother. 2006 Feb;40(2):286-9. Epub 2006 Jan 10. Review.

PMID:
16403850
16.

Lenalidomide in lymphomas and chronic lymphocytic leukemia.

Wiernik PH.

Expert Opin Pharmacother. 2013 Mar;14(4):475-88. doi: 10.1517/14656566.2013.765858. Epub 2013 Jan 29. Review.

PMID:
23356486
17.

Lenalidomide in the treatment of chronic lymphocytic leukemia.

Itchaki G, Brown JR.

Expert Opin Investig Drugs. 2017 May;26(5):633-650. doi: 10.1080/13543784.2017.1313230. Epub 2017 Apr 17. Review.

PMID:
28388253
18.

The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.

Palumbo A, Freeman J, Weiss L, Fenaux P.

Expert Opin Drug Saf. 2012 Jan;11(1):107-20. doi: 10.1517/14740338.2011.619975. Epub 2011 Nov 9. Review.

PMID:
22066855
19.

Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.

Morgan G.

Blood Rev. 2010 Nov;24 Suppl 1:S27-32. doi: 10.1016/S0268-960X(10)70006-0.

PMID:
21126634
20.

New immunomodulatory drugs in myeloma.

Lacy MQ.

Curr Hematol Malig Rep. 2011 Jun;6(2):120-5. doi: 10.1007/s11899-011-0077-y. Review.

PMID:
21327565

Supplemental Content

Support Center